Eric Tang

Joined AstraZeneca (formerly ICI) as lead biologist in 1992 and has led several drug hunting programmes in Cardiovascular and Respiratory / Inflammation disease area. From 1998 to 2008, I was leading a global effort in deploying automation and technology capabilities to support drug discovery projects across AstraZeneca sites in UK and US. Joining AZ Oncology Bioscience in 2003 as science leader, responsible to implement and deploy technology solutions to late stage Oncology portfolio within the Oncology groups in UK, Boston and Shanghai.

In 2008, assume leading responsibility to implement a global Oncology high throughput combination disease panel capability to accelerate the identification of novel-novel drug combination opportunities for both early and late stage AZ Oncology drugs with responsibility developing clinical-ready candidates for early clinical opportunities. In recently years, I am also responsible for the development and implementation of disease-relevant advanced in vitro microsphysiology systems for Oncology, including various 3D spheroid/organoid culture formats using both long term tumour cell panels and primary patient-derived tumour cells.